You Can Do Better Than SpaceX Right Now. Here Are 2 Stocks to Buy Instead.

The article argues that while SpaceX is a compelling business with a roughly $2 trillion market cap, its upside may be limited from here. It highlights Rivian as a discounted EV growth play with its R2 SUV starting under $50,000 and AI/autonomous driving exposure, and NuScale Power as a small-cap nuclear energy beneficiary of AI-driven data center power demand. The piece is largely opinion-driven analyst commentary rather than fresh company news, so direct market impact should be limited.

Analysis

The market is still treating these names as if optionality and execution risk are binary, but the more important second-order effect is capital scarcity. If growth capital remains concentrated in a few private mega-cap stories, smaller public names with credible stepping-stone products can re-rate sharply when they show any path to scale; that favors RIVN and SMR more than the headline narrative implies. In other words, the market is paying up for certainty in frontier tech while underpricing the convexity embedded in smaller caps that can improve sentiment with each milestone.

RIVN’s setup is less about the next vehicle launch and more about whether it can transition from “interesting EV story” to “manufacturing learning-curve beneficiary.” If the lower-price model broadens the addressable market, the stock can rerate on evidence of mix stabilization and margin inflection, not absolute unit growth alone. The key competitive dynamic is that every credible mass-market EV entrant forces legacy OEMs to defend share with price, which can squeeze weaker competitors and paradoxically make the strongest scaling EV platform the winner even in a slower industry.

SMR is a different trade: it is essentially a call option on AI-driven power scarcity. The market may be underestimating how quickly utilities and hyperscalers move from evaluating nuclear to pre-buying capacity once grid constraints become binding; that would show up first in partnerships and permitting, long before revenue scales. The main contrarian risk is that timelines slip by years, not quarters, and that can compress multiple expansion even if the end-state thesis remains intact.

The consensus may be missing that the biggest downside in both names is not thesis failure but dilution of attention and capital. If these companies need repeated financing before operating leverage emerges, equity holders may finance the transition while waiting for the market to believe the story. That argues for treating both as catalyst-driven trades rather than passive long-term holdings at current stages.

Key Decisions for Investors

• Long RIVN over a 3-6 month horizon into R2/launch execution updates; upside is a sentiment-driven multiple rerate if proof of demand and manufacturing discipline appears, but size modestly because dilution and margin misses can cut the equity in half quickly.
• Buy SMR as a 6-12 month event-driven option on AI power scarcity, but use spreads or a defined-risk call structure rather than stock; reward is outsized if commercial milestones accelerate, while downside is mostly time decay and financing overhang.
• Pair long RIVN / short a basket of higher-quality but slower-growth legacy auto names over 1-2 quarters if EV pricing pressure re-emerges; the trade benefits if investors rotate toward higher beta growth with visible catalysts.
• Avoid chasing TSLA off this read; the article’s signal is relative value, not a new inflection in the large-cap winner. If anything, TSLA’s lower implied upside makes it the funding source for a relative-long basket in smaller thematic names.
• If SMR gaps up on partnership headlines, take partial profits into strength and let the remainder run only if follow-through includes financing or regulatory progress; this is a classic ‘good news front-loads valuation’ setup.